✦ LIBER ✦

A phase I trial of a single high dose of idarubicin combined with high-dose cytarabine as induction therapy in relapsed or refractory adult patients with acute lymphoblastic leukemia

✍ Scribed by Weiss, M A; Drullinsky, P; Maslak, P; Scheinberg, D; Golde, D W

Book ID: 110053881
Publisher: Nature Publishing Group
Year: 1998
Tongue: English
Weight: 42 KB
Volume: 12
Category: Article
ISSN: 0887-6924
DOI: 10.1038/sj.leu.2401058

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A single, high dose of idarubicin combin

A single, high dose of idarubicin combined with cytarabine as induction therapy for adult patients with recurrent or refractory acute lymphoblastic leukemia

✍ Mark A. Weiss; Timothy B. Aliff; Martin S. Tallman; Stanley R. Frankel; Matt E. 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB

## Background: The majority of adult patients who are treated for lymphoblastic disease will either develop recurrent disease or will be refractory to their initial therapy. one option for patients with recurrent/refractory disease is to administer a reinduction regimen that employs a dose-intense

High-dose idarubicin in combination with

High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study

✍ Alessandra Tedeschi; Marco Montillo; Elena Strocchi; Anna Maria Cafro; Elisabett 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 338 KB

Combination of topotecan with cytarabine

Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: Results of a randomized phase I/II study

✍ Norbert Vey; Hagop Kantarjian; Miloslav Beran; Susan O'Brien; Jorge Cortes; Char 📂 Article 📅 1999 🏛 Springer US 🌐 English ⚖ 67 KB

Prospective randomized trial to evaluate

Prospective randomized trial to evaluate two delayed granulocyte colony stimulating factor administration schedules after high-dose cytarabine therapy in adult patients with acute lymphoblastic leukemia

✍ W. Hofmann; G. Seipelt; S. Langenhan; R. Reutzel; D. Schott; O. Schoeffski; H. I 📂 Article 📅 2002 🏛 Springer 🌐 English ⚖ 130 KB

A Phase I–II trial of escalating doses o

A Phase I–II trial of escalating doses of mitoxantrone with fixed doses of cytarabine plus fludarabine as salvage therapy for patients with acute leukemia and the blastic phase of chronic myelogenous leukemia

✍ Charles A. Koller; Hagop M. Kantarjian; Eric J. Feldman; Susan O'Brien; Mary Bet 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB 👁 2 views

## BACKGROUND. Cytarabine is an essential drug for inducing remission of acute myelogenous leukemia, and it is also one the most effective drugs used as salvage therapy for patients with all types of relapsed acute leukemia. Nevertheless, there is considerable room for improvement in the treatment

Lineage specific treatment of adult pati

Lineage specific treatment of adult patients with acute lymphoblastic leukemia in first remission with anti-B4-blocked ricin or high-dose cytarabine : Cancer and Leukemia Group B Study 9311

✍ Ted P. Szatrowski; Richard K. Dodge; Carol Reynolds; Carol A. Westbrook; Stanley 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 111 KB

## Background: Anti-b4-blocked ricin is an immunotoxin comprised of an anti-cd19 murine monoclonal antibody (b4) conjugated to blocked ricin, which has cytotoxic activity in patients with lymphoid malignancies. ## Methods: Adults with untreated acute lymphoblastic leukemia (all) were treated with